Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-[alpha], and Its Downregulation by Infliximab in Patients with Ulcerative Colitis

Background Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-[kappa]B in response to tumor necrosis factor (TNF)-[alpha]. Aims To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-[alpha] signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy. Methods In total, 31 IFX therapy-naïve patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-[alpha] and PRKCDBP expression was performed in rectal biopsies. Results A significant correlation was observed in immunoreactivity between TNF-[alpha] and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-[alpha] (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-[alpha] decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-[alpha] levels pre- and post-therapy (Spearman's rank correlation test; P = 0.005 and P = 0.001, respectively). Conclusions These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-[alpha] expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-[alpha]. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-[alpha], and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-[alpha]-PRKCDBP signaling pathway.